While murine monoclonal antibodies have made a major contribution to the field of diagnostic histopathology, their place as therapeutic reagents remains speculative. Many are capable of initiating human immune mechanisms and are interesting as potential biological response modifiers (Miller et al., 1983; Cheung et al., 1978) . Others are potentially useful in a wide variety of malignancies as passive delivery systems for drugs (Embleton et al., 1983; Kulkarni et al., 1981) , toxins (Jansen et al., 1982; Thorpe et al., 1985) and radio-isotopes (Larson et al., 1983; Carasquillo et al., 1984) .
Unfortunately, intravenous administration of '"'I radiolabelled antibodies to patients has met with limited success. This probably reflects the low levels of isotope accumulation in solid tumour deposits. Several tumour resection studies have demonstrated that only approximately 0.001% of injected dose binds to each gram of tumour (Esteban et al., 1987; Burraggi et al., 1985) . These levels are too low to deliver effective radiotherapy before marrow toxicity occurs (Humm, 1986; Vaughan et al., 1987) .
These observations led us and others (Lashford et al., 1988; Epenetos et al., 1987) to investigate the role of radiolabelled monoclonal antibodies in the treatment of intracavity extensions of tumour. The intrathecal compartment appears particularly amenable to this approach for three reasons. Firstly, neoplastic meningitis is essentially a leptomeningeal disease (Azzarelli, 1977; Olson et al., 1974) . Secondly, the CSF provides a natural circulatory mechanism for the distribution of antibodies. Finally, there is a clinical need to improve the therapy of this condition (Chessells, 1985; Cumberlin et al., 1979; Hitchins et al., 1987) . This paper reports the results of a pilot study of '"'I radiolabelled monoclonal antibodies in the treatment of leptomeningeal tumours.
Materials and methods

Patient selection
Patients included in the study had failed an adequate trial of conventional therapy and had evidence of leptomeningeal dissemination of tumour. To determine the degree of microaggregates and free iodine in the radiolabelled protein preparations, they were subjected to Sephacyl S300 column chromatography and precipitation with 10% trichloroaceric acid. In the first five administrations, immunological activity was assessed by an indirect immunofluoresence assay (Allan et al., 1983) . Due to the insensitivity of this technique, later preparations were assayed for the proportion of immunoreactive radiolabelled antibody in a direct radioimmunoassay under conditions of antigen excess (Zalutsky et al., 1989 Table I. Antibody preparation Antibody preparations were relatively free from microaggregates (mean value 1%, range 0.5%; n = 13), and free iodine (mean value 4.1%; range 1-13%; n = 14). In the first five patients, the antibody always retained biological activity as determined by the indirect immunofluoresence assay. In two of the remaining 10 radiolabellings, the immunoreactivity of the protein was substantially reduced (patients 6 and 12, less than 2% immunoreactive fraction).
Sites of isotope accumulation
The biodistribution of radionuclide, as demonstrated by scintigraphy, varied with both the pattern of tumour distribution and the antibody used. Some accumulation of "'1I in the liver and spleen was noted on all occasions. This was most UJl81.4
Radiation to T8-L1 (1,500 cGy). Neurological disturbance Two forms of neurological disturbance were observed in the study. Transient parasthesiae over sacral dermatomes was reported by patient 4. This symptom resolved within a few minutes of completing the injection. More concerning was the development of seizures in patients 10 and 14. Patient 10 presented with a history of progressive dementia and two grand mal seizures. In the week before therapy, the patient had signs of raised intracranial pressure and was deteriorating clinically. Injection of 58 mCi of radiolabelled HMFG1 produced a mild headache that lasted for 4-6 h. Forty-eight hours after administration of the conjugate, the patient was found drowsy and unresponsive. This state reversed in 20 min and was attributed to an unwitnessed seizure. The patient died suddenly 24 h later, possibly as a result of a further unwitnessed seizure.
Post-mortem revealed extensive involvement of the cerebral leptomeninges by tumour. In addition, marked acute oedematous and reactive changes were noted in the ventricular and subpial white matter. Milder oedematous changes were noted in white matter away from the CSF surfaces.
The second patient also received 60 mCi of`3'I HMFG1, The event-free survival of the responding group of patients is given in Table IV . This ranged from 7 to 26 months (mean 12; median 9.5 months treatment. Patient 8 developed solitary recurrences at 9 and 30 months and remains alive with disease 32 months from targeted therapy. Patient 14 remains alive and disease-free 26 months after treatment. The mean overall survival of the evaluable patients is 16 months with a median of 12 months.
Discussion
The central nervous system is a recognised site for secondary deposits of tumour. Tumour metastases may present as either solid parenchymal deposits or as a neoplastic meningitis. The frequency of the latter manifestation varies with tumour type, but is reported to occur in 4-5% of patients with nonHodgkin's lymphoma and in a substantial proportion of carcinomas.
This pilot study of '3'I monoclonal antibody has illustrated the potential for targeting such tumour sites. Five to seven days after treatment, scintigraphy demonstrated many areas of radionuclide accumulation which invariably correlated with the clinical and radiological pattern of the disease (Table II) . Despite this strong qualitative association between radioimmunolocalisation and clinical disease, we have not reported sensitivity of immunoscintigraphy as myelographic findings were frequently reported as 'multiple spinal deposits' and the imaging characteristics of the 13'I make it difficult to separate out small foci of disease in close proximity.
Of course, concordance between disease sites and radioimmunolocalisation cannot be taken as direct evidence of selective targeting. Non-specific localisation is possible due to both disturbed vascular flow in tumours and non-specific trapping within cysts (Primus et al., 1977; Goldenberg et al., 1974) . While is has been possible to demonstrate selective uptake of specific antibody on malignant cells in the CSF in one patient (patient 1) immunolocalisation was also noted in two patients administered radiolabelled monoclonal antibody with <2% immunoreactive fraction (patients 6 and 12) (Table II) . Consequently, we do not know if the accumulation of radionuclide in these patients was due to non-specific uptake of radionuclide or to the small fraction of immunoreactive antibody present in the preparation.
The toxicity of the administered conjugate may be attributed to both the antibody and the radionuclide. The high incidence of aseptic meningitis is felt to be due to the introduction of antibody into the CSF pathways as this complication has been reported with other intrathecally administered proteins such as human serum albumin (DiChiro, 1973) . The incidence of aseptic meningitis complicating cisternography was related to the preparation of 131I albumin and could be reduced by changing the albumin source. Consequently, more stringent quality control of intrathecally administered antibodies may reduce the frequency of this complication.
Other toxicities appear to be related to the dose of administered radionuclide. (Richardson et al., 1990) administration of antibodies and the other the intraventricular administration of conjugates.
The results from this study are sufficiently encouraging to continue with a full phase I/II study for patients with medulloblastoma, carcinomatous meningitis and lymphoproliferative disease within the CNS. It may also prompt other groups to investigate alternative targeted agents within a closed compartment such as the CSF pathways.
